# Immunofoco

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/immunofoco

- Industry: Biotechnology
- Headquarters: Shanghai, China
- Website: www.immunofoco.com/
- Total disclosed funding: $45M
- Latest round: Series B (Dec 26, 2025)
- Investors on record: 14

## About

Based in Zhangjiang, China and established in 2020, Shenzhen Immunofoco Biotechnology Co., Ltd., dba Immunofoco, is a clinical-stage biotech company that focuses on immune cell therapies for solid tumors. The company has developed multiple platforms including Peri Cruiser, SNR, T-Booster, and HTS. In 2022, its IMC002 (CLDN18.2 CAR-T) therapy received orphan drug designation (ODD) from the U.S. FDA and secured IND approvals in both China and the U.S. In 2023 and 2024, additional candidates such as IMC001 (EpCAM CAR-T) and IMC008 (SNR CAR-T) also received FDA ODD designations. Immunofoco has been recognized among China’s top potential unicorn enterprises and awarded several honors from national biopharmaceutical association. In March 2026, Immunofoco raised approximately CNY 200 million in Pre-IPO funding co-led by Gaorong Ventures and Jifeng Ventures, with participation from Shenzhen Investment Control Capital, Mingdao Investment, In Capital.
The company adopts immune cell therapy technology platforms to develop solid tumor therapeutics. Its product includes CAR-T products for solid tumors, including IMC001, IMC002 and IMC008. The company developed Peri Cruiser® technology platform which was designed to reduce the on-target, off-tumor (OTOT) toxicity in solid tumors.
The company generates revenue from developing immune cell therapy drugs.

## Funding rounds

- Series B, Dec 26, 2025 — Green Pine Capital Partners, Fosun Health Capital, Shenzhen Jinsheng Equity Investment Management, Shenzhen Nanshan Huirong Investment
- Series B, Oct 15, 2025 — Guangdong Technology Financial Group, Soochow Venture Investment, WinDigital Capital, Tppoly Capital
- Series A, Dec 30, 2022, $29M — SDIC Venture Capital, Tao Capital
- Series A, Jan 7, 2022, $16M — Delian Capital, Tao Capital, Shenzhen Qianhai Luojia Fangyuan Asset Management
- Angel, Feb 9, 2021 — ZhenFund, Tao Capital, Bohe Angel Fund

## Investors

- ZhenFund (https://capitalatlas.ai/funds/zhenfund) — Angel
- Tao Capital (https://capitalatlas.ai/funds/tao-capital) — Angel, Series A
- Bohe Angel Fund — Angel
- Delian Capital (https://capitalatlas.ai/funds/delian-capital) — Series A
- Shenzhen Qianhai Luojia Fangyuan Asset Management — Series A
- SDIC Venture Capital (https://capitalatlas.ai/funds/sdic-venture-capital) — Series A
- Guangdong Technology Financial Group (https://capitalatlas.ai/funds/guangdong-technology-financial-group) — Series B
- Soochow Venture Investment (https://capitalatlas.ai/funds/soochow-venture-investment) — Series B
- WinDigital Capital (https://capitalatlas.ai/funds/windigital-capital) — Series B
- Tppoly Capital (https://capitalatlas.ai/funds/tppoly-capital) — Series B
- Green Pine Capital Partners (https://capitalatlas.ai/funds/green-pine-capital-partners) — Series B
- Fosun Health Capital (https://capitalatlas.ai/funds/fosun-health-capital) — Series B
- Shenzhen Jinsheng Equity Investment Management — Series B
- Shenzhen Nanshan Huirong Investment — Series B